Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20117 in Participants With Advanced Solid Tumors
NCT05940116 is registered in ClinicalTrials.gov with Hansoh BioMedical R&D Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-20117 in Participants With Advanced Solid Tumors
- Lead sponsor
- Hansoh BioMedical R&D Company
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- July 20, 2023
- Completion date
- July 30, 2027
- Enrollment
- 322 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer, solid tumor